Following Share Rise, Hemispherx (HEB) Sets Up for Another Offering
More News related to HEB
- The Brualdi Law Firm, P.C. Announces Class Action Lawsuit Against Hemispherx Biopharma, Inc.
- Hemispherx Biopharma (HEB) Says Recently Filed Lawsuit is Without Merit
- Class Action Lawsuit Against Hemispherx Biopharma is Without Merit
- Brower Piven Encourages Investors Who Have Losses in Excess of $100,000 From Investment in Hemispherx Biopharma, Inc. to Inquire About the Lead Plaintiff Position in Securities Fraud Class Action Laws
- Izard Nobel LLP Announces Class Action Lawsuit Against Hemispherx Biopharma, Inc.
In a Form S-3, Hemispherx BioPharma (AMEX: HEB) filed a preliminary prospectus for a $150 million mixed securities shelf. The offering will include common stock, preferred stock, warrants and debt securities. Terms of the sale will be determined at the time of each offering.
Notably, Hemispherx just did an 11.9 million share equity offering on May 19. Despite pricing at a 30% discount from the previous close, shares of Hemispherx have doubled since this first offer.
After closing today's trading session down 6.9%, shares of Hemispherx have added another 3% to the intraday decline following the news. The stock most recently traded at $2.78.
Related Categories
Equity OfferingsTrader Talk
Stocks Mentioned
-0.01Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
